# RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

> **NCT02801097** · PHASE1 · TERMINATED · sponsor: **EpicentRx, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Malignant Solid Tumor
- Metastatic Cancer
- Advanced Cancer

## Interventions

- **DRUG:** RRx-001
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02801097
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-30
- **Primary completion:** 2018-11-22
- **Final completion:** 2019-12-09
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Sufficient patients enrolled to end study
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02801097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02801097, "RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02801097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*